Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

Non-small Cell Lung Cancer Clinical Trial

Official title:

Evaluation of Combination Checkpoint Inhibitor Plus Targeted Inhibitor (Erlotinib or Crizotinib) for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer: Phase Ib With Expansion Cohorts

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01998126
• Other study ID #: HCI66705
• Status: Completed
• Phase: Phase 1
• First received: July 11, 2013
• Last updated: March 30, 2018
• Start date: December 2, 2013
• Est. completion date: March 29, 2018

Study information

• Verified date: March 2018
• Source: University of Utah
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations. This is a modified phase I trial of immune checkpoint inhibitors in combination with mutation - specific targeted therapy (crizotinib or erlotinib) at conventional doses stratified for presence of ALK (Anaplastic lymphoma kinase) or EGFR (epidermal growth factor receptor) mutation.

The goals of the overall study are to evaluate a recommended phase 2 dose and the short and long term toxicities of the combinations.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 14
• Est. completion date: March 29, 2018
• Est. primary completion date: May 9, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of Stage IV Non-Small Cell Lung Cancer (NSCLC), or Stages II - III NSCLC that cannot be treated curatively with standard techniques.

• Non-Small Cell Lung Cancer (NSCLC) that is either EGFR or ALK mutated.

• Untreated with/or actively treated with specific inhibitor for less than 6 months if not progressing on active therapy.

• Age > 18.

• ECOG performance status 0, 1 or 2.

• Prior chemotherapy is allowed if > one month from the end of treatment. Patients must not have received chemotherapy within 4 weeks of the start of study drug.

• Brain metastases are allowed if the patient is asymptomatic or previous steroid treatment was discontinued > 6 weeks.

• Adequate bone marrow function as defined in the protocol

• Serum bilirubin levels < 1.5 mg/dL except for patients with Gilbert's syndrome.

• Adequate organ function as defined in the protocol

• If female and of childbearing potential, documentation of negative pregnancy test (serum or urine) within 7 days prior to first dose.

• Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.

Exclusion Criteria:

• Concurrent therapy with any other non-protocol anti-cancer therapy.

• History of any other malignancy requiring active treatment.

• Patients who have had a history of acute diverticulitis, intra-abdominal abscess, Gastrointestical obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.

• History of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre Syndrome). History of vitiligo and adequately controlled endocrine deficiencies such as hypothyroidism are allowed.

• Significant cardiovascular disease including:

• Active, clinically symptomatic left ventricular failure.

• Uncontrolled symptomatic hypertension that cannot be controlled with anti-hypertensive agents.

• Myocardial infarction, severe angina, or unstable angina within 6 months prior to administration of first dose of study drug.

• History of serious ventricular arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation)

• Cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with anti-arrhythmic medication)

• Coronary or peripheral artery bypass graft within 6 months of screening.

• Uncontrolled CNS metastases are not allowed; subjects with previously treated brain metastases will be allowed if the brain metastases have been treated, toxicities have resolved to grade 1 or baseline and steroids are no longer required. Leptomeningeal metastases are not allowed.

• Serious/active infection or infection requiring parenteral antibiotics.

• Pregnant or lactating females.

• HIV infection or chronic hepatitis B or C. Negative Screening tests for HIV, Hepatitis B, and Hepatitis C are required.

• The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Ipilimumab
Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
• Erlotinib
Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
• Crizotinib
Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
• Nivolumab

Locations

Country	Name	City	State
United States	Huntsman Cancer Institute	Salt Lake City	Utah

Sponsors (2)

Lead Sponsor	Collaborator
University of Utah	Bristol-Myers Squibb

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	toxicity of ipilimumab and erlotinib in EGFR mutated patients	The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.	36 months
Primary	toxicity of ipilimumab and crizotinib in ALK mutated patients	The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.	36 months
Primary	toxicity of nivolumab and erlotinib in EGFR mutated patients	The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.	36 months
Primary	toxicity of nivolumab and crizotinib in ALK mutated patients	The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab/nivolumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.	36 months
Secondary	Response rate		36 months
Secondary	Progression Free Survival (PFS)		36 months
Secondary	Overall Survival		36 months
Secondary	immune function pre and post immune therapy	The immune-related response criteria (irRC) incorporate several elements reflecting the complex tumor dynamics of ipilimumab treatment. Under these criteria, a measure of tumor volume is used that incorporates the contribution of new measurable lesions. Each net percentage change in tumor burden per assessment using irRC accounts for the size and growth kinetics of both old and new lesions as they appear. New lesions alone do not qualify as immune-related progressive disease.; In this study, immune-related response criteria (irRC) will be used to assess subject response to study treatment per investigator assessment. The secondary endpoint irPFS will be determined based on investigator assessment. In order to adequately address this secondary objective, investigators will follow the clinical practice guidelines to obtain additional tumor assessments beyond mWHO PD and follow the instructions in this section for the determination of immune-related response.	36 months